Pioneering method of treating Alzheimer’s discredited by scientists
Bexarotene, sold under the name Targretin, had caused ripples of excitement across the medical profession
A drug hailed as a pioneering method of treating Alzheimer’s has been discredited by scientists, after experts were unable to replicate its results this week.
Bexarotene, sold under the name Targretin, had caused ripples of excitement across the medical profession, following high profile research that suggested it could be used to treat the symptoms of Alzheimer’s.
The 2012 research, produced by Gary Landreth and colleagues at Case Western Reserve University in Cleveland and published in Science journal, reported that the drug appeared to reduce the brain plaque build-ups linked to the disease when administered to mice.
Once the results of the study were made public, patients began requesting the drug and some doctors reportedly began prescribing it.
However, a team of experts have now written in the same journal that they have been unable to re-create the results found in the original survey, plunging its validity into doubt.
Sangram Sisodia, professor of neuroscience at the University of Chicago, decided to investigate claims made that the drug could reduce the areas of plaque by 50 per cent within three days, and by 75 per cent in two weeks.
In his replica study published on Thursday, he said: “In view of the significant implications of these landmark findings for the development of novel AD therapeutics, we performed a small pilot study […] using 8-month-old male APP/PS1 mice that were treated orally with a commercial source of bexarotene for seven days.”
Crucially, he said: “We failed to observe any differences in hippocampal or cortical amyloid plaque area or plaque counts between vehicle and bexarotene-treated animals.”
Bexarotene was approved by the FDA in 1999 as a treatment for skin cancer, but has never before been tested as a treatment for humans with Alzheimer’s. Because it has been approved by the FDA it can be prescribed by physicians for use ‘off label.’
However, some scientists argued that whilst the effects on brain plaque had not been replicated, the cognitive improvements had.
Writing in Science, Professor Koldamova said: “We believe these findings make a solid case for continued exploration of bexarotene as a therapeutic treatment for Alzheimer's disease.”
- 2 California man brutally beat 82-year-old Sikh grandfather he mistook for 'one of those people'
- 3 School kitchen manager 'fired from Colorado school for giving hungry students free lunches'
- 5 Charles Kennedy 'had better judgement drunk than many sober politicians' says Ian Hislop
California man brutally beat 82-year-old Sikh grandfather he mistook for 'one of those people'
Amber Peat: Body found in search for missing 13-year-old who left house after argument with her parents
School kitchen manager 'fired from Colorado school for giving hungry students free lunches'
Isis executes three gay men by dangling them from top of 100ft building and letting go
Alton Towers crash: Four guests seriously injured as Smiler ride carriages collide
Thousands of teenage girls enduring debilitating illnesses after routine school cancer vaccination
Migrants in Kos: Photos show real tragedy after Brits abroad complain of 'awkward' holidays
British tourists complain that impoverished boat migrants are making holidays 'awkward' in Kos
Michael Gove determined to scrap the Human Rights Act – even if Scotland retains it
Threat to scrap Human Rights Act could see UK follow Nazi example, warns UN official
Church of England 'one generation away from extinction' after dramatic loss of followers
£40000 - £47000 per annum: Recruitment Genius: A 3rd Line Virtualisation / Sto...
£26000 - £35000 per annum: Recruitment Genius: A successful national service f...
£15000 - £25000 per annum: Recruitment Genius: This is an opportunity to join ...
£17500 - £20000 per annum: Recruitment Genius: We currently require an experie...